331771-20-1 | ZM 447439

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$79.00	$55.00
10mg	98%	in stock	$120.00	$84.00
25mg	98%	in stock	$219.00	$153.00
100mg	98%	in stock	$761.00	$533.00

Description

• Catalog Number: AF60813
• Chemical Name: ZM 447439
• CAS Number: 331771-20-1
• Molecular Formula: C29H31N5O4
• Molecular Weight: 513.5875
• MDL Number: MFCD08703125
• SMILES: COc1cc2c(ncnc2cc1OCCCN1CCOCC1)Nc1ccc(cc1)NC(=O)c1ccccc1

Computed Properties

• Complexity: 709
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 38
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 10
• XLogP3: 4.2

Literature

• Silver nanoparticle-induced phosphorylation of histone H3 at serine 10 is due to dynamic changes in actin filaments and the activation of Aurora kinases.

  Toxicology letters 20170705

• Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells.

  Nature cell biology 20140801

• Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.Na.

  Molecular cancer therapeutics 20140501

• Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition.

  Investigational new drugs 20120401

• Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin.

  Carcinogenesis 20120301

• Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.

  Journal of cancer research and clinical oncology 20120301

• Evolution of resistance to Aurora kinase B inhibitors in leukaemia cells.

  PloS one 20120101

• Geminin overexpression induces mammary tumors via suppressing cytokinesis.

  Oncotarget 20111201

• Formation of stable attachments between kinetochores and microtubules depends on the B56-PP2A phosphatase.

  Nature cell biology 20111001

• ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.

  The journal of obstetrics and gynaecology research 20110601

• Antiproliferative effect of Aurora kinase targeting in mesothelioma.

  Lung cancer (Amsterdam, Netherlands) 20101201

• Phosphorylation of histone H3 serine 10 in early mouse embryos: active phosphorylation at late S phase and differential effects of ZM447439 on first two embryonic mitoses.

  Cell cycle (Georgetown, Tex.) 20101201

• The Aurora kinase inhibitor ZM447439 accelerates first meiosis in mouse oocytes by overriding the spindle assembly checkpoint.

  Reproduction (Cambridge, England) 20101001

• Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways.

  Biochemical pharmacology 20100115

• ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines.

  Neuroendocrinology 20100101

• Trivalent dimethylarsenic compound induces histone H3 phosphorylation and abnormal localization of Aurora B kinase in HepG2 cells.

  Toxicology and applied pharmacology 20091215

• Aurora kinase B modulates chromosome alignment in mouse oocytes.

  Molecular reproduction and development 20091101

• Aurora kinase B, epigenetic state of centromeric heterochromatin and chiasma resolution in oocytes.

  Reproductive biomedicine online 20090901

• Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells.

  Molecular cancer therapeutics 20090701

• Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit.

  Molecular cancer therapeutics 20090601

• Discovery and development of aurora kinase inhibitors as anticancer agents.

  Journal of medicinal chemistry 20090514

• Short and long-term tumor cell responses to Aurora kinase inhibitors.

  Experimental cell research 20090415

• Investigating the role of Aurora kinases in RAS signaling.

  Journal of cellular biochemistry 20090101

• Regulation of the meiotic prophase I to metaphase I transition in mouse spermatocytes.

  Chromosoma 20081001

• Cell cycle dependent degradation of MCAK: evidence against a role in anaphase chromosome movement.

  Cell cycle (Georgetown, Tex.) 20081001

• Aurora kinase family: a new target for anticancer drug.

  Recent patents on anti-cancer drug discovery 20080601

• Molecular basis of drug resistance in aurora kinases.

  Chemistry & biology 20080601

• ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture.

  Cell cycle (Georgetown, Tex.) 20080515

• Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.

  Haematologica 20080501

• Requirement of aurora-A kinase in astral microtubule polymerization and spindle microtubule flux.

  Cell cycle (Georgetown, Tex.) 20080415

• A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia.

  Molecular cancer therapeutics 20070601

• Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests.

  International journal of radiation oncology, biology, physics 20070401

• MAPK interacts with XGef and is required for CPEB activation during meiosis in Xenopus oocytes.

  Journal of cell science 20070315

• Caffeine promotes apoptosis in mitotic spindle checkpoint-arrested cells.

  The Journal of biological chemistry 20070309

• Analysis of mitotic phosphorylation of borealin.

  BMC cell biology 20070101

• Inhibition of Aurora kinases perturbs chromosome alignment and spindle checkpoint signaling in rat spermatocytes.

  Experimental cell research 20061101

• Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients.

  Molecular cancer therapeutics 20061101

• Validating Aurora B as an anti-cancer drug target.

  Journal of cell science 20060901

• Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring.

  Journal of medicinal chemistry 20060810

• Histone post-translational modification: from discovery to the clinic.

  IDrugs : the investigational drugs journal 20060601

• Neither Aurora B activity nor histone H3 phosphorylation is essential for chromosome condensation during meiotic maturation of porcine oocytes.

  Biology of reproduction 20060501

• SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.

  Bioorganic & medicinal chemistry letters 20060301

• Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.

  Journal of medicinal chemistry 20060209

• Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase.

  FEBS letters 20050620

• The Ipl1/Aurora kinase family: methods of inhibition and functional analysis in mammalian cells.

  Methods in molecular biology (Clifton, N.J.) 20050101

• Dawn of Aurora kinase inhibitors as anticancer drugs.

  Expert opinion on investigational drugs 20040901

• Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.

  The Journal of cell biology 20030428